135 related articles for article (PubMed ID: 9815920)
1. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
Brooks D; Taylor C; Dos Santos B; Linden H; Houghton A; Hecht TT; Kornfeld S; Taetle R
Clin Cancer Res; 1995 Nov; 1(11):1259-65. PubMed ID: 9815920
[TBL] [Abstract][Full Text] [Related]
2. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects.
White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS
Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993
[TBL] [Abstract][Full Text] [Related]
3. Effects of monoclonal anti-transferrin receptor antibodies on in vitro growth of human solid tumor cells.
Taetle R; Honeysett JM
Cancer Res; 1987 Apr; 47(8):2040-4. PubMed ID: 3828993
[TBL] [Abstract][Full Text] [Related]
4. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies.
Taetle R; Castagnola J; Mendelsohn J
Cancer Res; 1986 Apr; 46(4 Pt 1):1759-63. PubMed ID: 3004704
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
[TBL] [Abstract][Full Text] [Related]
7. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia.
Sauvage CA; Mendelsohn JC; Lesley JF; Trowbridge IS
Cancer Res; 1987 Feb; 47(3):747-53. PubMed ID: 3802079
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
9. Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy.
Blottière HM; Steplewski Z; Herlyn D; Douillard JY
Hum Antibodies Hybridomas; 1991 Jan; 2(1):16-25. PubMed ID: 1908336
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.
Urba WJ; Ewel C; Kopp W; Smith JW; Steis RG; Ashwell JD; Creekmore SP; Rossio J; Sznol M; Sharfman W
Cancer Res; 1992 May; 52(9):2394-401. PubMed ID: 1533172
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
12. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
13. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
16. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
[TBL] [Abstract][Full Text] [Related]
17. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15.
Ball ED; Selvaggi K; Hurd D; Herzig R; Clark L; Malley V; Persichetti J; deMagelhaus-Silverman M
Clin Cancer Res; 1995 Sep; 1(9):965-72. PubMed ID: 9816068
[TBL] [Abstract][Full Text] [Related]
19. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.
Crépin R; Goenaga AL; Jullienne B; Bougherara H; Legay C; Benihoud K; Marks JD; Poul MA
Cancer Res; 2010 Jul; 70(13):5497-506. PubMed ID: 20530676
[TBL] [Abstract][Full Text] [Related]
20. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
